{
  "data": {
    "financials": {
      "sales_growth_3yr_avg": 17.07,
      "profit_growth_3yr_avg": 48.81,
      "roe_latest": 18.61,
      "roce_latest": 22.7,
      "pe_ratio": 18.3,
      "debt_to_equity": 0.12,
      "beta": 0.43
    },
    "dcf_inputs": {
      "free_cash_flow_latest_cr": 1847.0,
      "growth_rate_projection": 12.0,
      "shares_outstanding_cr": 83.46,
      "net_debt_cr": 4863.0,
      "tax_rate": 25.0
    },
    "qualitative": {
      "management_integrity_score": 8.5,
      "reasoning": "Dr. Reddy's Laboratories is a Nifty 50 constituent with a strong global presence and established governance structure. While it faces occasional regulatory observations (e.g., USFDA Form 483), which are typical for the sector, the management has a track record of transparency and remediation. The company maintains healthy return ratios and a conservative balance sheet."
    }
  },
  "_cached_at": "2025-12-24T22:06:44.962533",
  "_symbol": "DRREDDY"
}